Alexander Steinle

List of Publications by Year
in descending order

115	13,959	44069 48	25787 108
papers	citations	h-index	g-index

118	118	118	10957
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clr-f expression regulates kidney immune and metabolic homeostasis. Scientific Reports, 2022, 12, 4834.	3.3	1
2	The NKG2D ligand ULBP4 is not expressed by human monocytes. PLoS ONE, 2021, 16, e0246726.	2.5	0
3	Increased Concentrations of Circulating Soluble MHC Class I-Related Chain A (sMICA) and sMICB and Modulation of Plasma Membrane MICA Expression: Potential Mechanisms and Correlation With Natural Killer Cell Activity in Systemic Lupus Erythematosus. Frontiers in Immunology, 2021, 12, 633658.	4.8	10
4	Editorial: ADAM10 in Cancer Immunology and Autoimmunity: More Than a Simple Biochemical Scissor. Frontiers in Immunology, 2020, 11, 1483.	4.8	3
5	Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system. Expert Opinion on Biological Therapy, 2020, 20, 1491-1501.	3.1	10
6	MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA. Frontiers in Immunology, 2020, 11, 960.	4.8	9
7	Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature, 2019, 572, 254-259.	27.8	246
8	The NKG2D axis: an emerging target in cancer immunotherapy. Expert Opinion on Therapeutic Targets, 2019, 23, 281-294.	3.4	34
9	CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. Blood Advances, 2019, 3, 3674-3687.	5.2	40
10	Impairment of NKG2D-Mediated Tumor Immunity by TGF-Î². Frontiers in Immunology, 2019, 10, 2689.	4.8	92
11	Select Clr-g Expression on Activated Dendritic Cells Facilitates Cognate Interaction with a Minor Subset of Splenic NK Cells Expressing the Inhibitory Nkrp1g Receptor. Journal of Immunology, 2018, 200, 983-996.	0.8	5
12	The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma. Cancer Immunology, Immunotherapy, 2018, 67, 935-947.	4.2	21
13	Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells. OncoImmunology, 2018, 7, e1364827.	4.6	72
14	NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma. Clinical Cancer Research, 2018, 24, 882-895.	7.0	73
15	A point mutation in the <i>Ncr1</i> signal peptide impairs the development of innate lymphoid cell subsets. OncoImmunology, 2018, 7, e1475875.	4.6	9
16	Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4. Frontiers in Immunology, 2018, 9, 620.	4.8	19
17	Cellular Mechanisms Controlling Surfacing of AICL Glycoproteins, Cognate Ligands of the Activating NK Receptor NKp80. Journal of Immunology, 2018, 201, 1275-1286.	0.8	6
18	Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion. Blood, 2018, 132, 769-769.	1.4	2

#	Article	IF	Citations
19	The Activating C-type Lectin-like Receptor NKp65 Signals through a Hemi-immunoreceptor Tyrosine-based Activation Motif (hemITAM) and Spleen Tyrosine Kinase (Syk). Journal of Biological Chemistry, 2017, 292, 3213-3223.	3.4	7
20	Clr-a: A Novel Immune-Related C-Type Lectin-like Molecule Exclusively Expressed by Mouse Gut Epithelium. Journal of Immunology, 2017, 198, 916-926.	0.8	12
21	HemITAM: A single tyrosine motif that packs a punch. Science Signaling, 2017, 10, .	3.6	22
22	The Smac Mimetic BV6 Improves NK Cell-Mediated Killing of Rhabdomyosarcoma Cells by Simultaneously Targeting Tumor and Effector Cells. Frontiers in Immunology, 2017, 8, 202.	4.8	18
23	Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma. Frontiers in Immunology, 2017, 8, 387.	4.8	38
24	Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors. Frontiers in Immunology, 2017, 8, 1466.	4.8	20
25	The Stalk Domain of NKp30 Contributes to Ligand Binding and Signaling of a Preassembled NKp30-CD3Î¶ Complex. Journal of Biological Chemistry, 2016, 291, 25427-25438.	3.4	9
26	Human hematopoietic CD34+ progenitor cells induce natural killer cell alloresponses via NKG2D activation. Experimental Hematology, 2016, 44, 14-23.e1.	0.4	1
27	Key residues at the membraneâ€distal surface of <scp>KACL</scp>, but not glycosylation, determine the functional interaction of the keratinocyteâ€specific <scp>C</scp>â€type lectinâ€like receptor <scp>KACL</scp> with its highâ€affinity receptor <scp>NK</scp>p65. Immunology, 2015, 145, 114-123.	4.4	9
28	MULT1plying cancer immunity. Science, 2015, 348, 45-46.	12.6	6
29	An Fcâ€optimized NKG2Dâ€immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia. International Journal of Cancer, 2015, 136, 1073-1084.	5.1	32
30	Dedicated immunosensing of the mouse intestinal epithelium facilitated by a pair of genetically coupled lectin-like receptors. Mucosal Immunology, 2015, 8, 232-242.	6.0	16
31	Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids. BMC Cancer, 2015, 15, 351.	2.6	74
32	Novel APC-like properties of human NK cells directly regulate T cell activation. Journal of Clinical Investigation, 2015, 125, 1763-1763.	8.2	1
33	MIC Molecules. , 2015, , 2812-2816.		0
34	Transferrinâ€˜ activation: Bonding with transferrin receptors tunes <scp>KLRG</scp>1 function. European Journal of Immunology, 2014, 44, 1600-1603.	2.9	3
35	Fc-Optimized NKG2Dâ€“Fc Constructs Induce NK Cell Antibody-Dependent Cellular Cytotoxicity against Breast Cancer Cells Independently of HER2/neu Expression Status. Journal of Immunology, 2014, 193, 4261-4272.	0.8	33
36	Altered MicroRNA Expression after Infection with Human Cytomegalovirus Leads to TIMP3 Downregulation and Increased Shedding of Metalloprotease Substrates, Including MICA. Journal of Immunology, 2014, 193, 1344-1352.	0.8	41

#	Article	IF	Citations
37	A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro-Oncology, 2014, 16, 382-391.	1.2	49
38	MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. Oncotarget, 2014, 5, 7651-7662.	1.8	79
39	Shedding of endogenous MHC class Iâ€related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the â€œa disintegrin and metalloproteasesâ€• 10 and 17. International Journal of Cancer, 2013, 133, 1557-1566.	5.1	170
40	Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends in Immunology, 2013, 34, 182-191.	6.8	262
41	Attenuated Natural Killer (NK) Cell Activation through C-type Lectin-like Receptor NKp80 Is Due to an Anomalous Hemi-immunoreceptor Tyrosine-based Activation Motif (HemITAM) with Impaired Syk Kinase Recruitment Capacity. Journal of Biological Chemistry, 2013, 288, 17725-17733.	3.4	11
42	Modulation of NK Cell Function by Genetically Coupled C-Type Lectin-Like Receptor/Ligand Pairs Encoded in the Human Natural Killer Gene Complex. Frontiers in Immunology, 2013, 4, 362.	4.8	79
43	New prospects on the NKG2D/NKG2DL system for oncology. OncoImmunology, 2013, 2, e26097.	4.6	109
44	Genetically coupled receptorâ€"ligand pair NKp80-AICL enables autonomous control of human NK cell responses. Blood, 2013, 122, 2380-2389.	1.4	35
45	BACL Is a Novel Brain-Associated, Non-NKC-Encoded Mammalian C-Type Lectin-Like Receptor of the CLEC2 Family. PLoS ONE, 2013, 8, e65345.	2.5	7
46	Platelets Impair NK Cell Immunosurveillance Of Metastasizing Tumor Cells By Altering Surface Expression and Shedding Of Ligands For The Activating Immunoreceptor NKG2D. Blood, 2013, 122, 3488-3488.	1.4	3
47	Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D. Cancer Research, 2012, 72, 460-471.	0.9	172
48	Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses. Journal of Immunology, 2012, 189, 1360-1371.	0.8	179
49	Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction. International Journal of Cancer, 2012, 131, 1601-1610.	5.1	18
50	Induction of NK Cell Reactivity in Breast Cancer by Fc-Engineered NKG2D-Ig Fusion Proteins. Blood, 2012, 120, 253-253.	1.4	0
51	CD155 is involved in NK-cell mediated lysis of human hepatoblastoma in vitro. Frontiers in Bioscience - Elite, 2011, E3, 1456-1466.	1.8	12
52	The Polymorphic HCMV Glycoprotein UL20 Is Targeted for Lysosomal Degradation by Multiple Cytoplasmic Dileucine Motifs. Traffic, 2011, 12, 1444-1456.	2.7	12
53	Editorial overview. Cellular and Molecular Life Sciences, 2011, 68, 3453-3455.	5.4	1
54	Cutting Edge: NKp80 Uses an Atypical Hemi-ITAM To Trigger NK Cytotoxicity. Journal of Immunology, 2011, 186, 657-661.	0.8	42

#	Article	IF	Citations
55	Vis-Ã-Vis in the NKC: Genetically Linked Natural Killer Cell Receptor/Ligand Pairs in the Natural Killer Gene Complex (NKC). Journal of Innate Immunity, 2011, 3, 227-235.	3.8	41
56	MIC Molecules. , 2011, , 2282-2285.		0
57	The BCR/ABLâ€inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. International Journal of Cancer, 2010, 127, 2119-2128.	5.1	75
58	Interaction of C-type lectin-like receptors NKp65 and KACL facilitates dedicated immune recognition of human keratinocytes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5100-5105.	7.1	50
59	Conserved Amino Acids within the Adenovirus 2 E3/19K Protein Differentially Affect Downregulation of MHC Class I and MICA/B Proteins. Journal of Immunology, 2010, 184, 255-267.	0.8	21
60	Structure of the HCMV UL16-MICB Complex Elucidates Select Binding of a Viral Immunoevasin to Diverse NKG2D Ligands. PLoS Pathogens, 2010, 6, e1000723.	4.7	52
61	NKG2D and Its Ligands In Leukemia: Comprehensive Analysis of Expression, Release and Modulation of NK Cell Reactivity.. Blood, 2010, 116, 1686-1686.	1.4	2
62	Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B. Clinical Cancer Research, 2009, 15, 5208-5215.	7.0	168
63	Interferonâ€Î³ downâ€regulates NKG2D ligand expression and impairs the NKG2Dâ€mediated cytolysis of MHC class Iâ€deficient melanoma by natural killer cells. International Journal of Cancer, 2009, 124, 1594-1604.	5.1	85
64	Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the Î±2 domain. European Journal of Immunology, 2009, 39, 1642-1651.	2.9	14
65	Inhibition of hepatitis B virus replication by small interference RNA induces expression of MICA in HepG2.2.15 cells. Medical Microbiology and Immunology, 2009, 198, 27-32.	4.8	19
66	NKp80 defines and stimulates a reactive subset of CD8 T cells. Blood, 2009, 113, 358-369.	1.4	45
67	Reinforcing natural killers. Blood, 2009, 113, 6042-6043.	1.4	1
68	NK cells and cancer immunosurveillance. Oncogene, 2008, 27, 5932-5943.	5.9	572
69	Induction of MHC class I-related chain B (MICB) by 5-aza-2â€²-deoxycytidine. Biochemical and Biophysical Research Communications, 2008, 370, 578-583.	2.1	58
70	Macrophage Migration Inhibitory Factor Contributes to the Immune Escape of Ovarian Cancer by Down-Regulating NKG2D. Journal of Immunology, 2008, 180, 7338-7348.	0.8	144
71	Interaction of Monocytes with NK Cells upon Toll-Like Receptor-Induced Expression of the NKG2D Ligand MICA. Journal of Immunology, 2008, 181, 6711-6719.	0.8	111
72	Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma. Clinical Cancer Research, 2008, 14, 3520-3528.	7.0	78

#	Article	IF	Citations
73	Tumor-Associated MICA Is Shed by ADAM Proteases. Cancer Research, 2008, 68, 6368-6376.	0.9	322
74	Soluble NKG2D ligands: prevalence, release, and functional impact. Frontiers in Bioscience - Landmark, 2008, Volume, 3448.	3.0	119
75	CLEC2A: a novel, alternatively spliced and skin-associated member of the NKC-encoded AICLâ€"CD69â€"LLT1 family. Immunogenetics, 2007, 59, 903-912.	2.4	30
76	Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. Anticancer Research, 2007, 27, 2041-5.	1.1	29
77	Natural Killer Cell-Mediated Rejection of Experimental Human Lung Cancer by Genetic Overexpression of Major Histocompatibility Complex Class I Chain-Related Gene A. Human Gene Therapy, 2006, 17, 135-146.	2.7	42
78	Release of MICB Molecules by Tumor Cells: Mechanism and Soluble MICB in Sera of Cancer Patients. Human Immunology, 2006, 67, 188-195.	2.4	119
79	Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nature Immunology, 2006, 7, 1334-1342.	14.5	211
80	Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunology, Immunotherapy, 2006, 55, 1584-1589.	4.2	113
81	Soluble MICA in malignant diseases. International Journal of Cancer, 2006, 118, 684-687.	5.1	207
82	TGF-Â and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain, 2006, 129, 2416-2425.	7.6	194
83	BCR/ABL Oncogene Directly Controls MHC Class I Chain-Related Molecule A Expression in Chronic Myelogenous Leukemia. Journal of Immunology, 2006, 176, 5108-5116.	0.8	126
84	Proteolytic Release of Soluble UL16-Binding Protein 2 from Tumor Cells. Cancer Research, 2006, 66, 2520-2526.	0.9	211
85	Human Cytomegalovirus-Encoded UL16 Discriminates MIC Molecules by Their Î±2 Domains. Journal of Immunology, 2006, 177, 3143-3149.	0.8	31
86	Expression of tollâ€like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates ILâ€8 release, and upâ€regulation of NKG2Dâ€ligands. FASEB Journal, 2006, 20, 118-120.	0.5	81
87	Natural Killer Cell-Mediated Rejection of Experimental Human Lung Cancer by Genetic Overexpression of Major Histocompatibility Complex Class I Chain-Related Gene A. Human Gene Therapy, 2006, .	2.7	0
88	Systemic NKG2D Down-Regulation Impairs NK and CD8 T Cell Responses In Vivo. Journal of Immunology, 2005, 175, 720-729.	0.8	211
89	Activation of VÎ³9VÎ´2 T Cells by NKG2D. Journal of Immunology, 2005, 175, 2144-2151.	0.8	282
90	Natural Killer Cellâ€"Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate. Cancer Research, 2005, 65, 6321-6329.	0.9	349

#	Article	IF	Citations
91	RNA Interference Targeting Transforming Growth Factor-Î² Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity<i>In vivo</i>. Cancer Research, 2004, 64, 7596-7603.	0.9	275
92	VÎ´1 T Lymphocytes from B-CLL Patients Recognize ULBP3 Expressed on Leukemic B Cells and Up-Regulated by Trans-Retinoic Acid. Cancer Research, 2004, 64, 9172-9179.	0.9	166
93	The Innate Immune Response in the Central Nervous System and Its Role in Glioma Immune Surveillance. Oncology Research and Treatment, 2004, 27, 487-491.	1.2	22
94	Downregulation and/or Release of NKG2D Ligands as Immune Evasion Strategy of Human Neuroblastoma. Neoplasia, 2004, 6, 558-568.	5.3	216
95	Prevalent expression of the immunostimulatory MHC class I chainâ€“related molecule is counteracted by shedding in prostate cancer. Journal of Clinical Investigation, 2004, 114, 560-568.	8.2	241
96	Prevalent expression of the immunostimulatory MHC class I chainâ€“related molecule is counteracted by shedding in prostate cancer. Journal of Clinical Investigation, 2004, 114, 560-568.	8.2	158
97	Novel APC-like properties of human NK cells directly regulate T cell activation. Journal of Clinical Investigation, 2004, 114, 1612-1623.	8.2	136
98	Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. European Journal of Immunology, 2003, 33, 194-203.	2.9	220
99	Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood, 2003, 102, 1389-1396.	1.4	483
100	MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Research, 2003, 63, 8996-9006.	0.9	158
101	Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding. Journal of Immunology, 2002, 169, 4098-4102.	0.8	565
102	Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics, 2001, 53, 279-287.	2.4	428
103	Complex structure of the activating immunoreceptor NKG2D and its MHC class Iâ€“like ligand MICA. Nature Immunology, 2001, 2, 443-451.	14.5	352
104	Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA. Science, 1999, 285, 727-729.	12.6	2,677
105	Recognition of Stress-Induced MHC Molecules by Intestinal Epithelial Î³Î´ T Cells. Science, 1998, 279, 1737-1740.	12.6	1,093
106	Diversification, expression, and Î³Î´ T cell recognition of evolutionarily distant members of the MIC family of major histocompatibility complex class I-related molecules. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 12510-12515.	7.1	106
107	The HLA Likes and Dislikes of Allospecific and Non-MHC-Restricted Cytotoxic T Lymphocytes. Immunological Reviews, 1996, 154, 105-135.	6.0	7
108	Motif of HLA-B*3503 peptide ligands. Immunogenetics, 1995, 43, 105-107.	2.4	31

#	Article	IF	Citations
109	In vivo expansion of HLA-B35 alloreactive T cells sharing homologous T cell receptors: evidence for maintenance of an oligoclonally dominated allospecificity by persistent stimulation with an autologous MHC/peptide complex.. Journal of Experimental Medicine, 1995, 181, 503-513.	8.5	40
110	Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells.. Journal of Experimental Medicine, 1995, 182, 1005-1018.	8.5	43
111	HLA class I alleles of LCL 721 and 174XCEM.T2 (T2). Tissue Antigens, 1994, 44, 268-270.	1.0	36
112	Microheterogeneity in HLA-B35 alleles influences peptide-dependent allorecognition by cytotoxic T cells but not binding of a peptide-restricted monoclonal antibody. Human Immunology, 1993, 38, 261-269.	2.4	28
113	Isolation and characterization of a genomic HLAâ€Cw6 clone. Tissue Antigens, 1992, 39, 134-137.	1.0	23
114	Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control. Open Research Europe, 0, 1, 107.	2.0	1
115	Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control. Open Research Europe, 0, 1, 107.	2.0	1